Aldeyra Therapeutics, Inc. (ALDX)
Healthcare
Biotechnology
1.50 $
-3.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Aldeyra Therapeutics, Inc. (ALDX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 87.3% of the shares are freely tradable; institutional investors hold 62.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
62.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
3.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
87.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
11.8%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
60Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Knoll Capital Management LP | 9.08 | 5,475,516 | +0.0 | 03/31/2026 |
| BlackRock Inc | 6.24 | 3,763,887 | -2.2 | 03/31/2026 |
| Vanguard Group Inc | 6.13 | 3,698,682 | +3.0 | 12/31/2025 |
| AQR Capital Management LLC | 4.69 | 2,829,875 | +130.6 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.92 | 2,363,742 | +0.0 | 03/31/2026 |
| Kingdon Capital Management LLC | 3.57 | 2,152,315 | +16.3 | 03/31/2026 |
| 683 Capital Management LLC | 2.49 | 1,500,000 | -2.0 | 03/31/2026 |
| D. E. Shaw & Co LP | 2.33 | 1,403,990 | -12.3 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.96 | 1,784,433 | +0.0 | 04/30/2026 |
| iShares Russell 2000 ETF | 2.21 | 1,333,213 | +0.9 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.